Ok so from the last quarterly IHL-216A for Concussion and...

Ok so from the last quarterly IHL-216A for Concussion and Traumatic Brain Injury is expected to be done, hopefully results soon
and on track


For IHL-675A multi-use drug candidate for Lung Inflammation, Rheumatoid Arthritis, and Inflammatory Bowel Disease, trial should have begun Q4 2021


Results must be due soon based on this:



For IHL-42X for Obstructive Sleep Apnoea the Company has been granted a pre-IND meeting with FDA on May 11. Planning commences for pivotal clinical trials to commence after opening an IND with FDA. So should get feedback this quarter.


For Psilocybin-assisted Psychotherapy for General Anxiety Disorder (Psi-GAD). As per the last quarterly therapist training for the phase 2a trial assessing psilocybin-assisted therapy for Generalised Anxiety Disorder is completed; patient recruitment to commence imminently. So probably not much on this until Q3?



Also - aren't we waiting on a second psychedelics trial to be announced? See here

And they need to explain to us what this acquisition is all about

Plenty of fish to fry in Q2 2022